Home > Insider Trading > Filing (0000950170-24-081748)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818794	Dyne Therapeutics Inc.	DYN	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1691005	Gatti Susanna High	1560 Trapelo Road Waltham MA 02451	Chief Operating Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-06-21	29,787	$5.54	178,579	No	4	M	Direct
Common Stock	Disposition	2024-06-21	29,787	$35.01	148,792	No	4	S	Direct
Common Stock	Acquisiton	2024-06-24	10,213	$5.54	159,005	No	4	M	Direct
Common Stock	Disposition	2024-06-24	10,213	$35.33	148,792	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2024-06-21	29,787	$0.00	29,787	$5.54
Common Stock	Stock option (right to buy)	Disposition	2024-06-24	10,213	$0.00	10,213	$5.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,699		2030-07-30	No	4	M	Direct
60,486		2030-07-30	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.63, inclusive.
Includes 134,629 unvested RSUs.
The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.